IRF1 Cancer Research Results

IRF1, interferon regulatory factor 1: Click to Expand ⟱
Source:
Type:

IRF1 (interferon regulatory factor 1) is a transcription factor induced by interferons, pattern-recognition signalling, inflammatory cytokines and DNA damage. IRF1 activates genes involved in innate and adaptive immunity, antigen processing and presentation, growth arrest and programmed cell death. In many cancers, IRF1 expression or function is reduced, deleted or inhibited, which can weaken tumour immune surveillance and permit proliferation, survival and treatment resistance. Restoration or activation of IRF1 can increase MHC class I antigen presentation, support cytotoxic immune responses, induce cell-cycle arrest and promote apoptosis or other inflammatory forms of tumour-cell death. The typical cancer-associated direction is therefore commonly down or functionally suppressed, while the desired anticancer modulation is generally up or restoration of IRF1 activity. However, because IRF1 also regulates inflammatory and immune-checkpoint genes, its effects can vary with tumour type and immune context.



Pca, Prostate Cancer: Click to Expand ⟱
Prostate Cancer: Alterations in genes such as ERG, SPOP, MYC, androgen receptor (AR), and CHD1, drive PCa progression.
TP53 is the most commonly mutated gene in human cancer.
HH↑, GLI-1↑, SHH↑ P53↓
The loss of p53 and/or other tumor suppressor genes, reduced capacity for DNA repair, the dysfunction of telomerase activity, and changes in the pathways that govern the growth of cells also mediate the progression of Pca.
It has been well documented that Ca2+ influx and MDR1 upregulation are highly associated with GEM metabolism in human pancreatic carcinoma.
Increased Growth factor IGF-1/IGF-1R axis activation mediated by both PI3K/Akt or RAF/MEK/ERK system and AR expression remains important in the development and progression of prostate cancer.
It has been demonstrated that prostate cancer cells are relatively sensitive to heat stress.
Long non-coding RNA MALAT1 has been reported as an oncogenic target in multiple types of cancers, including PC.
Scientific Papers found: Click to Expand⟱
7137- GI,    6-Shogaol from dried ginger inhibits growth of prostate cancer cells both in vitro and in vivo through inhibition of STAT3 and NF-κB signaling
- in-vitro, Pca, LNCaP - in-vitro, Pca, DU145 - in-vitro, Pca, PC3 - vitro+vivo, Pca, HMVP2
STAT3↓, TNF-α↓, NF-kB↓, cycD1/CCND1↓, survivin↓, cMyc↓, IL7↓, RANTES↓, BAX↑, Bcl-2↓, P21↑, p27/CDKN1B↑, SOCS1↑, IRF1↑, eff↑, TumVol↓, TumW↓, toxicity↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

IL7↓, 1,   IRF1↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

cMyc↓, 1,  

Cell Death(tgid=5) ⓘ

BAX↑, 1,   Bcl-2↓, 1,   p27/CDKN1B↑, 1,   survivin↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

cycD1/CCND1↓, 1,   P21↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

STAT3↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

NF-kB↓, 1,   RANTES↓, 1,   SOCS1↑, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

eff↑, 1,  

Functional Outcomes(tgid=23) ⓘ

toxicity↓, 1,   TumVol↓, 1,   TumW↓, 1,  
Total Targets: 18

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: IRF1, interferon regulatory factor 1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:22  Cells:%  prod#:%  Target#:1585  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page